For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Hims & Hers Health Inc (NYSE: HIMS) was $42.99 for the day, down -3.54% from the previous closing price of $44.57. In other words, the price has decreased by -$3.54 from its previous closing price. On the day, 17.73 million shares were traded. HIMS stock price reached its highest trading level at $44.83 during the session, while it also had its lowest trading level at $42.97.
Ratios:
Our analysis of HIMS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 83.43. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65. TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 25 ’25 when Boughton Soleil bought 2,571 shares for $44.53 per share.
Dudum Andrew sold 128,127 shares of HIMS for $5,773,242 on Aug 18 ’25. The Chief Executive Officer now owns 89,521 shares after completing the transaction at $45.06 per share. On Aug 18 ’25, another insider, Dudum Andrew, who serves as the Chief Executive Officer of the company, sold 47,534 shares for $45.05 each. As a result, the insider received 2,141,492 and left with 142,592 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 9716599808 and an Enterprise Value of 9616354304. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 53.80, and their Forward P/E ratio for the next fiscal year is 54.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.83 while its Price-to-Book (P/B) ratio in mrq is 17.25. Its current Enterprise Value per Revenue stands at 4.776 whereas that against EBITDA is 60.044.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.13, which has changed by 1.8969002 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $13.47. The 50-Day Moving Average of the stock is -16.52%, while the 200-Day Moving Average is calculated to be 6.04%.
Shares Statistics:
HIMS traded an average of 38.59M shares per day over the past three months and 23327590 shares per day over the past ten days. A total of 217.38M shares are outstanding, with a floating share count of 202.65M. Insiders hold about 10.34% of the company’s shares, while institutions hold 77.78% stake in the company. Shares short for HIMS as of 1753920000 were 64593744 with a Short Ratio of 1.67, compared to 1751241600 on 68345051. Therefore, it implies a Short% of Shares Outstanding of 64593744 and a Short% of Float of 35.459998.
Earnings Estimates
A detailed examination of Hims & Hers Health Inc (HIMS) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.26, with high estimates of $0.31 and low estimates of $0.17.
Analysts are recommending an EPS of between $1.24 and $0.78 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.77 and $0.99.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 11 analysts are estimating revenue of $631.31M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $592.7M.
A total of 13 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 12 analysts’ estimates, the company’s revenue will be $2.8B in the next fiscal year. The high estimate is $3B and the low estimate is $2.5B.
